Purpose: Glioneuronal tumors (GNTs) are the most common histological type of brain tumors in patients who received epilepsy surgery, and part of them presented with BRAF V600E mutation. We aimed to verify the presence of the BRAF V600E mutation in epilepsy-associated GNTs from Chinese population and evaluate the association with clinical features. Methods: Data from 35 patients diagnosed with GNTs, including 24 gangliogliomas and 11 dysembryoplastic neuroepithelial tumors, were retrospectively collected. DNA was extracted from GNTs tissues and BRAF V600E mutation was examined by DNA sequencing. The correlations between BRAF V600E mutation and clinical features were analyzed. Results: Totally, BRAF V600E mutations were detected in 11 patients with GNTs, the rate of mutation were 33.3% and 27.3% in GGs (8/24) and DNTs (3/11), respectively. The probability of BRAF V600E mutation in females (7/12, 58.3%) was significantly higher than that in males (4/23, 17.4%) (P = 0.022). Moreover, patients with BRAF-mutated GNTs had a significantly wider variety of seizure types compared to GNTs with BRAF wild-type status (P =0.027). However, no significant correlation between the BRAF status and certain clinical features, such as age of seizure onset, duration of epilepsy, age at surgery, location of the tumor and postoperative seizure free, were observed. Conclusion: We demonstrated the presence of BRAF V600E mutation in Chinese epileptic patients with GNTs, which was significantly correlated with gender and multiple seizure types. Large sample studies and long-term follow-up are required for further confirmation.
Introduction
Every fourth patient who received epilepsy surgery suffers from a brain tumor according to the data from the European Epilepsy Brain Bank [1] . Glioneuronal tumors (GNTs), including gangliogliomas (GGs) and dysembryoplastic neuroepithelial tumors (DNTs), are the most common histological type. These slowly growing tumors are located in neocortex and related symptoms usually manifest themselves at an early age, with seizures as the most prominent and often the only neurological symptom.
Microscopically, they manifest neuronal in addition to glial differentiation, characterized by mixed neuroepithelial cell types, including dysmorphic neuronal cells and glial elements [2] . Cortical dysplasia often coexists, which suggests a developmental pathogenesis for these lesions [1] [2] [3] . With the development of epilepsy surgery, GNTs have been attracting more and more attention.
The serine threonine kinase v-RAF murine sarcoma viral oncogene homologue B1 (BRAF) gene is a member of the RAF family of serine/threonine protein kinases involved in the RAS/ RAF/MEK/ERK kinase signaling pathway [4, 5] . As a key mediator, BRAF participates in cell cycle regulation, including cell proliferation, cell cycle arrest, terminal differentiation, and apoptosis [6, 7] . Oncogenic alterations of BRAF have been previously observed in various human cancers, including melanoma, colon cancer, thyroid carcinoma and the others [4] . Missense mutations at amino acid position 600 account for the vast majority of BRAF mutations, resulting in an exchange of valine by glutamate in the activating segment of the kinase domain of BRAF, which is referred to as BRAF V600E [5] . Recently, BRAF V600E mutations were detected in up to 50% GGs and in a few DNTs [3, 5, 6] . However, the data of BRAF V600E mutations in Chinese population is lacking, and its correlation with clinicopathological features in epileptic patients has been rarely explored before.
In the present study, we collected the clinical and pathological data of 35 epileptic patients with GNTs. Our aim was to verify the presence of the BRAF V600E mutation in epilepsy-associated GNTs from Chinese population and investigate the association with clinical characteristics.
Methods

Subjects
From the database of the Epilepsy Center at the Second Affiliated Hospital, School of Medicine, Zhejiang University, we reviewed data of 208 patients operated for epilepsy, between September 2012 to March 2016. Among these, 35 cases diagnosed with GNTs (including 24 GGs and 11 DNTs) were retrieved, according to the 2007 revised World Health Organization (WHO) classification of tumors of the central nervous system [8] . 24 of the samples were re-confirmed by the Department of Pathology, Medical Center, University of California at Los Angeles.
A detailed medical history including demographic profiles, clinical features as age at seizure onset, duration of epilepsy, seizure type, past history (i.e., head trauma, hypoxia-ischemia brain injury, encephalitis), family history of epilepsy and brain tumor, febrile seizures, non-invasive long-term video electroencephalogram (VEEG) results, magnetic resonance imaging (MRI) findings and postoperative seizure onset time, medication and seizure outcome were obtained in all patients (n = 35). Multiple seizure types were defined as two or more seizure types, which included simple partial seizure, complex partial seizure, partial seizure evolving to secondarily generalized seizure, etc [9] . The follow-up period were 3 months or more. The study was approved by the Ethics Committee of Second Affiliated Hospital, School of Medicine, Zhejiang University.
Tumor specimens preparation
Brain tumor specimens were fixed in 10% buffered formalin and embedded in paraffin. These tissue were sectioned at 4 mm and underwent hematoxylin & eosin (HE), as well as for a number of immunohistochemical markers (such as synaptophysin, glial fibrillary acidic protein, neuronal nuclear protein, CD34, P53 S-100, and Ki67) if diagnosis was required.
DNA extraction and BRAF V600E mutation analysis
Areas of the representative tumor identified on HE stained sections were selected and marked, DNA was extracted from 7 mm thick sections of formalin-fixed paraffin-embedded (FFPE) tissue using QIAamp DNA FFPE Tissue Kit (QIAGNE Cat No: 56404, Germany) according to the manufacturer's instructions. Polymerase chain reaction (PCR) amplifications and sequencing for codon 600 of BRAF were performed as previously described [5] . Purified PCR products were sequenced using sequenced using the ABI3730xl sequencer (Applied Biosystems, Foster City, CA).
Statistical analysis
All analyses were performed with SPSS 22.0 software. The continuous variables were described with mean and ranges; categorical variables with proportions and percentages. The student's t test was used to assess differences between the groups (age at seizure onset, age at surgery and duration of epilepsy), while the two-tailed chi-square or Fisher's exact tests was used to assess correlations between BRAF V600E mutation and the other clinical features (multiple seizure types, location, drug-resistant epilepsy, postoperative seizure free, etc.). The p value of <0.05 was considered as statistically significant. Additionally, "time-toevent" data analysis on postoperative seizure free was calculated with the Kaplan-Meier method, and the differences between the curves were evaluated by the log-rank test. All the patients accepted surgical treatment, including lesionectomy and epileptogenic focus resection, and the postoperative course was uneventful. There were 24 GGs and 11 DNTs. The pathological subtype of the latter was all simple form. Evidence of focal cortical dysplasia (FCD) was detected in 8 GGs, which was also referred to as FCD type IIIb [10] .
With follow-up for at least 3 months, approximately 77% of patients (27/35) achieved seizure free. The other 8 patients reported significant reduction in seizure frequency.
Clinical characteristics of patients are summarized in Table 1 .
BRAF V600E mutations in GNTs
Totally, BRAF V600E mutations were found in 11 patients by DNA sequencing, including 8 GGs (mutation frequency 33.3%) and 3 DNTs (mutation frequency 27.3%). Of which, there were 4 males and 7 females (Table 2 ). In the mutation group, the mean age of seizure onset was 20.0 (1-51), the mean duration of epilepsy was 5.3 (0.1-18) years, and the mean age at surgery was 25.3 (6-53). 72.7% of theses (8/11) were patients with intractable epilepsy, and 72.7% (8/11) had multiple seizure types.
Most of the BRAF V600E mutant GNTs (9/11, 81.8%) were located in the temporal lobe. Only 3 of them were found to be associated with FCD. 81.8% of the patients (9/11) with BRAF V600E mutations obtained postoperative seizure free lasting more than 3 months.
Correlation between BRAF V600E mutation and clinical features of GNTs
For GNTs, we found that the probability of BRAF V600E mutation in females (7/12, 58.3%) was significantly higher than that in males (4/23, 17.4%) (P = 0.022). Moreover, patients with BRAF-mutated GNTs had a significantly wider variety of seizure types compared to GNTs with BRAF wild-type status (P = 0.027). However, no significant association between the BRAF status and several clinical features, including age of seizure onset, duration of epilepsy, age at surgery, febrile convulsion, drug-resistant epilepsy, location of the tumor (temporal; extratemporal), coexisting with FCD and postoperative seizure free, were observed ( Table 2 ). The cumulative time-dependent probability of postoperative seizure freedom was also performed, which was seen in Fig. 1 . There was no statistical significance in the probability of seizure freedom between patients with BRAF mutation and wild-type BRAF status (P = 0.733).
27 patients (8 had BRAF V600E mutation) with intractable epilepsy were selected for further evaluation. In this subgroup, the results between BRAF-mutated and wild-type group were in agreement with the above analysis (for gender, P = 0.001; for multiple seizure types, P = 0.013).
GGs subgroup analysis also showed there was a significant association between BRAF status and multiple seizure types (P = 0.032), but for gender, no statistic difference was observed (P = 0.099). Considering the limited sample size, we did not analyze the DNTs subgroup.
Discussion
GNTs are generally low-grade gliomas defined as mixed neuronal-glial tumors. A seizure frequency of up to 100% is seen with DNTs, and of 80-90% in GGs [11] . Epilepsy associated with GNTs is often poorly controlled by antiepileptic drugs. Therefore, GNTs are also classified into long-term epilepsy-associated tumors, but at the same time, are high responsive to surgical treatment [12] . In the present study, we collected a cohort of 35 epileptic patients with GNTs. We found that the clinical and pathological features were basically consistent with previous reports [13] [14] [15] . As shown in our study, GNTs were more common in men (male: female = 2:1), and always manifest themselves with an early onset but prolonged epilepsy, which is in accordance with most prior studies [16] [17] [18] . Besides, according to our results, GNTs were most commonly located in the temporal lobe [2, 6] . We also observed that partial seizure (mainly complex) was the most common seizure type, and about half of the patients had two or more types of seizure.
Currently, BRAF V600E mutations were found in variable frequencies across a wide spectrum of diverse central nervous system neoplasms, especially glial and glioneuronal tumors, which have caused the extensive concern [4] . Notably, detection of BRAF V600E mutation may be valuable in the diagnostic evaluation of GNTs [3] . Accordingly, the incidence of BRAF V600E mutation in GGs ranges from 16-67% and it is more common in paediatric patients [4, 5] . Schindler et al. analysed BRAF V600E mutation in 1320 nervous system tumors from Europe and north America and found the mutation frequencies in GGs was 18% [5] . Chappé et al. [19] from France reported that BRAF V600E mutation was detected in 38.7% GGs. Another research described that the incidence of BRAF V600E mutation in paediatric GGs was about 50%, but only about 20% observed were in adult GGs [20] . Whereas in DNTs, BRAF V600E mutation was observed in about 30% [3, 20, 21] . Here, we confirmed the occurrence of the BRAF V600E mutation in 11 out of 35 patients (31.4%), while the rate of mutation was 33.3% and 27.3% respectively in GGs and DNTs. The findings of our study were consistent with previous studies. To the best of our knowledge, our research represented the first of its kind in Chinese epileptic patients. Different results reported may be due to the variety of sample size, test method (immunohistochemistry or DNA sequencing), detection process and race.
Our study evaluated BRAF V600E mutation and clinical correlation in GNTs, which have rarely been reported previously. In the current cohort, we observed that the mutation frequency of BRAF V600E in female patients was significantly higher than that in male patients, especially for those with refractory epilepsy. This had been described in colon cancer, papillary thyroid carcinoma and lung cancer as well [22] [23] [24] , which might be directly or indirectly related to sex hormones, but the mechanism remains unknown. However, study of Prabowo et al. [3] reported that no statistically significant association between the BRAF status and gender was found, suggesting that race might be one of the possible factors to be considered. In a word, the association with gender is intriguing and warrant further verification.
Furthermore, the presence of BRAF V600E mutation was also significantly associated with multiple seizure types. The semiology in epileptic seizures was related to epileptogenic zone and spread network [25] . We speculated that there were complex interactions between BRAF V600E mutation and seizures. The mutation might influence neural network, causing the abnormal discharge of various types of neurons in different locations, which contribute to the various seizure type. This, however, remains to be confirmed by further studies. Our previous study provided evidence that patients with multiple seizure types might achieve late remission [9] . One of the possible mechanisms could be intrinsic disease severity. It could be determined by a predetermined, complex interaction between underlying pathology, individual genetics and the environment, reflecting the pattern of seizure outcome [9] . Interestingly, almost all of our patients with multiple seizure types were drug resistant. Thus, it might imply that BRAF V600E mutation may result in multiple seizure types, leading to the medication refractoriness in those patients.
Similar to Prabowo et al. [3] , we did not detect a correlation between the BRAF alterations and the age of seizure onset or other clinical variables, such as duration of epilepsy, age at surgery, tumor location and coexisting with FCD. Dahiya et al. [26] reported a series of pediatric gangliogliomas, and the results suggested a slightly worse recurrence-free survival of tumors with BRAF V600E mutant. Nevertheless, the prognostic significance of the BRAF V600E mutation in GNTs is less well established and understood [27] . This may be attributed to the overall small number and the inconsistent conclusions on survival data of the significantly more diverse group of tumors with the BRAF V600E mutation [28] . Unlike the previous studies, our research objects were epileptic patients. Hence, we paid more attention to the improvement of seizures after surgery. In previous studies, the expression of BRAF V600E was found to be associated with a worse postoperative seizure outcome in GNTs [3] . However, we had obtained an inconsistent result that seizure outcome after surgery was not related to BRAF V600E mutation. Considering the short term of follow-up, the association between BRAF V600E mutation and postoperative epilepsy prognosis requires further confirmation.
The study has some limitations. First, the follow-up period of some cases was relatively short, and the result of seizure free could change as time went on, besides, the sample size was not very large, which limited our further subgroup analysis and the ability to provide more accurate results. Second, our case series was undertaken at a local tertiary center, thus the result may not be representative for all regions across China. Large sample studies and long-term follow-up are required to confirm the validity of our findings.
Conclusion
In conclusion, GNTs represented a well-recognized cause of intractable epilepsy in children and young adults, most patients achieved favorable seizure free after surgery. We have demonstrated the presence of BRAF V600E mutation in Chinese epileptic patients with GNTs, which was significantly correlated with gender and multiple seizure types. Besides, more studies are needed to better understand the value of BRAF V600E mutations in GNTs and their possible role as a potential prognostic indicator of postoperative seizure outcome.
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